467 related articles for article (PubMed ID: 12784334)
1. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
[TBL] [Abstract][Full Text] [Related]
3. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
4. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
6. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
7. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
12. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
14. Pathobiology and prognosis of chromophobe renal cell carcinoma.
Klatte T; Han KR; Said JW; Böhm M; Allhoff EP; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Urol Oncol; 2008; 26(6):604-9. PubMed ID: 18367104
[TBL] [Abstract][Full Text] [Related]
15. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.
Blute ML; Leibovich BC; Cheville JC; Lohse CM; Zincke H
J Urol; 2004 Aug; 172(2):465-9. PubMed ID: 15247704
[TBL] [Abstract][Full Text] [Related]
16. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy.
Boorjian SA; Crispen PL; Lohse CM; Leibovich BC; Blute ML
J Urol; 2008 Jul; 180(1):99-103; discussion 103. PubMed ID: 18485415
[TBL] [Abstract][Full Text] [Related]
17. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
18. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome.
Canfield SE; Kamat AM; Sánchez-Ortiz RF; Detry M; Swanson DA; Wood CG
J Urol; 2006 Mar; 175(3 Pt 1):864-9. PubMed ID: 16469567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
